
Rare Disease Health Care Access Study 2020 RESULTS





ABOUT THE COUNCIL

In 2019 the rare disease community passed bill SF973 calling for the creation of a Rare Disease Advisory Council.

The bill passed unanimously and was endorsed by 42 organizations across patient advocacy groups, hospital systems, industry, and medical associations...

the Chloe Barnes Advisory Council on Rare Diseases was formed.





The Chloe Barnes Advisory Council on Rare Diseases has been 'diagnosing' the rare disease patients' barriers to care in Minnesota since 2019.

THE

WHY

Made up of 24 members that span five health care institutions and multiple patient groups, the vision of the Council is a society where every patient with a rare disease has access to a timely diagnosis, appropriate care, and effective treatment.

Recognizing persistent barriers to health care for the rare disease community, the council needed health care access research to effectively change the trajectory of rare disease patients' diagnosis odyssey.



Rare Disease Frontline Provider Survey KEY TAKEAWAYS





LIMITED SPECIALTY KNOWLEDGE

Nearly a quarter of providers do not think

their knowledge of rare diseases meets the needs of their practice.









Over **75**%

of clinicians are somewhat or **not at all comfortable interpreting genetic testing results.**





OUT-OF-STATE REFERRALS



say that they never or **very rarely** have to **refer difficult to diagnose** rare disease patients out of state.



LIMITED LOCAL CARE

Rare disease specialists are mainly in the Twin Cities metro area.

There are a limited number of specialists to treat rare disease outside the metro area.









		٦
l al		
	-	

report that many times the type of insurance the patients carries has affected their ability to complete the recommended treatment plan.






60% of providers and dentists identify transitioning care from pediatrics to adult as difficult.







56% and **60%** of medical and dental providers who reported having **difficulty transitioning** their patients reported it was due to a local practitioner being unwilling to take the patient.








Over 90% of providers felt (depending on the type of training) they **would benefit from additional training.**







INABILITY TO PROVIDE CARE

30% of medical and dental providers **did not feel** that they had the **ability to care for rare disease** patients who have contacted them.



77% because the disease was too complex and lesser numbers reported time constraints, out of the scope, and/or ability of their practice.



ADDITIONAL STUDIES TO BE LEVERAGED


GAO, October 2021

Rare Diseases: Although Limited, Available Evidence Suggests Medical and Other Costs Can Be Substantia

What GAO Found

According to the literature GAO reviewed, diagnosis of any disease can be complicated, and diagnosis of rare diseases can be particularly difficult because of a variety of factors. (See figure.) Although some rare diseases may be detected quickly, in other cases years may pass between the first appearance of symptoms and a correct diagnosis of a rare disease, and misdiagnoses—and treatments based on them—occur with documented frequency. According to the literature GAO reviewed and GAO's interviews, those with undiagnosed, misdiagnosed, or untreated rare diseases may face various negative outcomes. For example, a person's health can suffer when appropriate, timely interventions are not provided or when interventions based on misdiagnoses cause harm. In addition, multiple diagnostic tests, medical appointments, and ultimately unwarranted interventions can add to the costs of the disease.

Examples of Factors That May Interfere with Accurate Diagnosis



The National Economic Burden of Rare Disease Study



FEBRUARY 25, 2021

PREPARED FOR:

PREPARED BY:





